PRESS RELEASE published on 07/23/2024 at 07:30, 1 year 6 months ago Inside Information / News release on accounts, results GenSight Biologics reports cash position of €6.9 million as of June 30, 2024, with potential over 100 vials available upon Q3 resumption of early access program. Company confirms sufficient working capital and successful blending step for LUMEVOQ drug product Working Capital Business Update Cash Position GenSight Biologics LUMEVOQ Drug Product
BRIEF published on 07/11/2024 at 07:35, 1 year 6 months ago GenSight Biologics Launches Newsletter for Retail Investors Financial Updates Gene Therapy Retail Investors LUMEVOQ® Optogenetics
PRESS RELEASE published on 07/11/2024 at 07:30, 1 year 6 months ago Inside Information / Other news releases GenSight Biologics launches a newsletter for retail investors providing updates, news articles, conferences, and financial figures in French, available via subscription on the company's website Subscription Retail Investors Newsletter French GenSight Biologics
BRIEF published on 06/20/2024 at 07:35, 1 year 7 months ago GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates Gene Therapy Operational Update GenSight Biologics Financial Negotiation
PRESS RELEASE published on 06/20/2024 at 07:30, 1 year 7 months ago Inside Information / Other news releases GenSight Biologics renegotiates financial obligations and provides operational updates, with successful capital increases enhancing short-term flexibility Financial Obligations Operational Updates GenSight Biologics Capital Increases Gene Therapies
BRIEF published on 06/04/2024 at 07:35, 1 year 8 months ago GenSight Biologics to Present at Key Medical Conferences in 2024 Gene Therapy GenSight Biologics Medical Conferences 2024 LUMEVOQ® LHON
PRESS RELEASE published on 06/04/2024 at 07:30, 1 year 8 months ago Inside Information / Other news releases GenSight Biologics to present at key medical and stakeholder meetings, including 16th Meeting of the EUNOS. Papers on LUMEVOQ® for LHON to be showcased Gene Therapy GenSight Biologics Medical Conferences LUMEVOQ Retinal Neurodegenerative Diseases
BRIEF published on 06/03/2024 at 07:35, 1 year 8 months ago GenSight Biologics Welcomes William Monteith to the Board of Directors Board Of Directors Nomination GenSight Biologics William Monteith Gene Therapies
BRIEF published on 05/23/2024 at 11:40, 1 year 8 months ago Crossing thresholds for GENSIGHT BIOLOGICS SA Actions Crossing Thresholds GenSight Biologics Armistice Capital Subscription Warrants
BRIEF published on 05/07/2024 at 19:34, 1 year 9 months ago GenSight Biologics Announces Availability of Prospectus for New Shares Listing on Euronext Paris Euronext Paris Capital Increase Gene Therapy Prospectus GenSight Biologics
Published on 02/07/2026 at 01:00, 1 day 5 hours ago Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 1 day 7 hours ago Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 1 day 8 hours ago Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 1 day 15 hours ago Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 1 day 17 hours ago Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange
Published on 02/07/2026 at 21:00, 9 hours 43 minutes ago Alibaba Group Debuts 'Wonder on Ice,' an Immersive AI Experience at Milan’s Sforza Castle for Milano Cortina 2026
Published on 02/07/2026 at 16:35, 14 hours 8 minutes ago The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 14 hours 23 minutes ago NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 1 day 11 hours ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 1 day 12 hours ago EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG
Published on 02/06/2026 at 18:22, 1 day 12 hours ago Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 1 day 14 hours ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/05/2026 at 18:06, 2 days 12 hours ago Aéroports de Paris SA - Shares and voting rights as of 31 January 2026
